1.Simultaneous determination of panaxynol and panaxydol in fibrous root of Panax ginseng by HPLC.
Jie LI ; Juan JIANG ; Yimin ZHENG ; Linlin WANG ; Yuqing YANG ; Yang HU
China Journal of Chinese Materia Medica 2011;36(17):2380-2382
OBJECTIVETo establish an HPLC method for simultaneous determination of panaxynol and panaxydol from the fibrous root of Panax ginseng.
METHODThe analysis was performed on Elite C18 column (4.6 mm x 150 mm, 5 microm) with mobile phase gradient of CH3CN-water at a flow rate of 1.0 mL x min(-1). The detection wavelength was 230 nm, and the detection temperature was ambient.
RESULTThe linear range were 0.70-3.50 microg (r = 0.9995) for panaxynol, and 0.64-3.20 microg (r = 0.9999) for panaxydol. The average recoveries were 99.1% (RSD 1.7%) and 99.3% (RSD 1.2%), respectively.
CONCLUSIONThe HPLC method is simple, rapid and reproducible, which can be used for the quality control of the fibrous root of P. ginseng.
Chromatography, High Pressure Liquid ; methods ; Diynes ; analysis ; Drugs, Chinese Herbal ; analysis ; Fatty Alcohols ; analysis ; Panax ; chemistry ; Plant Roots ; chemistry
2.Inhibition of panaxynol on experimental delayed type hypersensitivity.
Min HONG ; Jie ZHENG ; Liang WANG ; Ye KUANG ; Hongmei WEN ; Xinzhi WANG
China Journal of Chinese Materia Medica 2010;35(8):1034-1037
OBJECTIVETo evaluate the effect of panaxynol (PAN) on delayed type hypersensitivity and possible mechanism.
METHODAllergic contact dermatitis (ACD) was induced by DNCB as a delayed type hypersensitivity (DTH) model to observe effect of PAN on auricle inflammation including pathological injury. Proliferation of T lymphocytes was induced by ConA and measured by MTf method. IFN-gamma secretion of splenocyte induced by ConA was detected by ELISA.
RESULTThe swelling degree of auricle and pathological injury in ACD mice was reduced significantly by treated with PAN in induction phase. Proliferation of T lymphocytes induced by ConA in vitro was inhibited significantly by PAN, By contrast, no detectable effect was observed in resting splenocyte. IFN-y induced by ConA in splenocytes was inhibited markedly by PAN from 10 micromol x L(-1) and from 6 h.
CONCLUSIONThe results showed that DTH was inhibited by PAN mainly in induction phase and this effect may be related with the inhibition on T lymphocytes proliferation and secretion of IFN-gamma.
Animals ; Cell Proliferation ; drug effects ; Concanavalin A ; metabolism ; Dermatitis, Allergic Contact ; drug therapy ; immunology ; metabolism ; Diynes ; pharmacology ; therapeutic use ; Fatty Alcohols ; pharmacology ; therapeutic use ; Female ; Interferon-gamma ; secretion ; Male ; Mice ; Mice, Inbred ICR ; Spleen ; drug effects ; pathology ; secretion ; T-Lymphocytes ; drug effects ; pathology
3.Pharmacokinetic profiles of falcarindiol and oplopandiol in rats after oral administration of polyynes extract of Oplopanax elatus.
Wei SUN ; Yi-Sheng HE ; Ling-Hui XU ; Bi-Ying ZHANG ; Lian-Wen QI ; Jie YANG ; Ping LI ; Xiao-Dong WEN
Chinese Journal of Natural Medicines (English Ed.) 2016;14(9):714-720
Polyynes, such as facarindiol (FAD) and oplopandiol (OPD), are responsible for anticancer activities of Oplopanax elatus (O. elatus). A novel approach to pharmacokinetics determination of the two natural polyynes in rats was developed and validated using a liquid chromatography-electrospray ionization-mass spectrometry (LC-MS) method. Biosamples were prepared by liquid-liquid extraction using ethyl acetate/n-hexane (V : V = 9 : 1) and the analytes were eluted on an Agilent ZORBAX Eclipse Plus C18 threaded column (4.6 mm × 50 mm, 1.8 μm) with the mobile phase of acetonitrile-0.1% aqueous formic acid at a flow-rate of 0.5 mL·min(-1) within a total run time of 11 min. All analytes were simultaneously monitored in a single-quadrupole mass spectrometer in the selected ion monitoring (SIM) mode using electrospray source in positive mode. The method was demonstrated to be rapid, sensitive, and reliable, and it was successfully applied to the pharmacokinetic studies of the two polyynes in rat plasma after oral administration of polyynes extract of O. elatus.
Administration, Oral
;
Animals
;
Chromatography, High Pressure Liquid
;
methods
;
Diynes
;
administration & dosage
;
pharmacokinetics
;
Drugs, Chinese Herbal
;
administration & dosage
;
pharmacokinetics
;
Fatty Alcohols
;
administration & dosage
;
pharmacokinetics
;
Male
;
Naphthols
;
administration & dosage
;
pharmacokinetics
;
Oplopanax
;
chemistry
;
Polyynes
;
administration & dosage
;
pharmacokinetics
;
Rats
;
Rats, Sprague-Dawley
;
Spectrometry, Mass, Electrospray Ionization
;
methods
4.Comparison of the pharmacokinetics of lidamycin in mice determined by two methods.
You-ping LIU ; Quan-sheng LI ; Yu-rong HUANG ; Chang-xiao LIU
Acta Pharmaceutica Sinica 2004;39(9):695-699
AIMTo compare two methods, the total radioactivity assay (RA method) and the radioactivity assay after separation with high performance liquid chromatography (HPLC-RA method).
METHODS125I-Lidamycin was prepared by Iodogen method and separated by size exclusive high performance liquid chromatography. The pharmacokinetic parameters of lidamycin were assayed by two methods after intravenous injection to mice at the dose of 100 microg x kg(-1), and compared by statistical analysis.
RESULTSThe pharmacokinetic parameters (Vd, T1/2alpha, T1/2beta, K21, K10, K12, AUC and CL) showed significant difference between the two methods (P < 0.05).
CONCLUSIONThe HPLC-RA method was better than the RA method to determine unchanged 125I-lidamycin.
Aminoglycosides ; blood ; pharmacokinetics ; Animals ; Antibiotics, Antineoplastic ; blood ; pharmacokinetics ; Area Under Curve ; Chromatography, High Pressure Liquid ; methods ; Enediynes ; Female ; Iodine Radioisotopes ; Isotope Labeling ; Male ; Mice ; Sensitivity and Specificity
5.Potentiation and mechanism of cisplatin-induced apoptosis by lidamycin in human hepatoma BEL-7402 cells.
Hong-zun LIU ; Dian-dong LI ; Yong-su ZHEN ; Rong-guang SHAO
Acta Pharmaceutica Sinica 2003;38(4):250-254
AIMTo investigate the synergetic effect and the mechanism of antitumor action of the antibiotic lidamycin in combination with cisplatin in vitro.
METHODSCytotoxicity of the drugs was measured by clonogenic assay. Chromatin condensation was observed by co-staining with fluorescent dyes, Hoechst 33342 and propidium iodide. Apoptotic sub-G1 was detected by flow cytometry and DNA ladder was observed using agarose gel electrophoresis. Bcl-2 protein level was detected by Western blot assay.
RESULTSBy using clonogenic assay, lidamycin in combination with cisplatin was found to have synergetic effects on the proliferation of human hepatoma BEL-7402 cells. The data showed that BEL-7402 cells treated with cisplatin and lidamycin in combination produced internucleosomal DNA fragmentation analysed by agarose gel electrophoresis. The results of flow cytometry showed that cisplatin and lidamycin administrated in combination showed no obvious change in G1 phase distribution compared with single treatment. However, this combination reduced the S phase arrest and reversed the reduction of G2/M phase induced by single treatment. The results also showed that there was 11.3% or 9.37% of cells undergoing apoptosis in BEL-7402 cells treated with cisplatin or lidamycin, respectively, while it showed 32.4% of apoptotic cells in combination treatment. Cisplatin, lidamycin and combination of cisplatin and lidamycin was shown to induce typical chromatin condensation in BEL-7402 cells. The study showed that 0.5 mumol.L-1 cisplatin or 1 x 10(-4) mumol.L-1 lidamycin alone decreased Bcl-2 protein level, while lidamycin in combination with cisplatin strongly inhibited expression of Bcl-2 proteins in BEL-7402 cells.
CONCLUSIONThe results suggest that lidamycin enhancement of cisplatin-induced apoptosis associates with decrease of Bcl-2 protein expression, which may be useful for cancer chemotherapy.
Aminoglycosides ; pharmacology ; Antibiotics, Antineoplastic ; pharmacology ; Antineoplastic Agents ; pharmacology ; Apoptosis ; Carcinoma, Hepatocellular ; pathology ; Cisplatin ; pharmacology ; Drug Synergism ; Enediynes ; Humans ; Liver Neoplasms ; metabolism ; pathology ; Proto-Oncogene Proteins c-bcl-2 ; metabolism ; S Phase ; drug effects ; Tumor Cells, Cultured
6.Lidamycin metabolism in vitro.
Yan-qing WEN ; Zhi-yun MENG ; Shu-zhen CHEN ; Xiao-xia ZHU ; Gui-fang DOU
Acta Pharmaceutica Sinica 2011;46(9):1132-1136
This paper is to report the study of the metabolism of lidamycin in vitro including in plasma and microsomes to guide clinical therapy. Lidamycin was quantified by detecting its active ingredient using HPLC-MS/MS. The metabolic stability of lidamycin in rat, Beagle dog, monkey and human plasma and liver microsomes, and its inhibition to cytochrome P450 isoforms in human liver microsomes were studied. Results showed that lidamycin was metabolized in the four species of plasma, and the sequence of metabolic rates in plasma were in rat > in dog > in human > in monkey. But among the four species of liver microsomes, lidamycin was metabolized only in monkey liver microsomes. There was almost no inhibition to cytochrome P450 isoforms at the concentrations of between 0.0005 and 10 ng x mL(-1). Therefore, the property of lidamycin metabolism in human is similar with that in dog, and metabolism of other drugs would not be decreased by cytochrome P450 as used along with lidamycin in clinic.
Aminoglycosides
;
blood
;
metabolism
;
Animals
;
Antibiotics, Antineoplastic
;
blood
;
metabolism
;
Chromatography, High Pressure Liquid
;
Cytochrome P-450 CYP1A2
;
metabolism
;
Cytochrome P-450 Enzyme System
;
metabolism
;
Dogs
;
Enediynes
;
blood
;
metabolism
;
Enzyme Activation
;
Humans
;
Macaca
;
Microsomes, Liver
;
metabolism
;
Rats
;
Tandem Mass Spectrometry
7.Chemosensitivity of mdr1 gene overexpressed multidrug resistant cancer cells to lidamycin.
Yi-Kang SHI ; Shu-Ying WU ; Yun-Hong HUANG ; Yong-Su ZHEN
Acta Pharmaceutica Sinica 2006;41(12):1146-1151
AIMTo investigate the chemosensitivity to lidamycin (C-1027) in mdr1 gene overexpressing cancer cell lines established by drug induction and by gene-transfection.
METHODSDNA was cloned by RT-PCR and then eukaryotic expressing recombinant plasmid pcDNA3. 1/mdrl was constructed. Using Lipofectamine 2000, a strain of stably transfected human hepatoma cancer cells, HepG2/mdrl, was obtained. The mdr1 mRNA level, P-glycoprotein (P-gp) level and the activity of P-gp to extrude drugs in cancer cells were determined by RT-PCR, immunofluorescence analysis and rhodamine 123 efflux assay. The chemosensitivity of cancer cells with low or high mdr1 expression to lidamycin and other antitumor drugs was tested by MTT assay.
RESULTSThe mdr1 mRNA and P-gp levels in KBv200, MCF-7/ADR, and stably transfected HepG2/mdr1 cells were much higher than that in respective parent KB, MCF-7 and HepG2 cells. The IC50 values of lidamycin for KBv200, MCF-7/ADR and HepG2/mdrl cells were (0.24 +/- 0.20) nmol x L(-1), (0.028 +/- 0.011) nmol x L(-1), and (0.020 +/- 0.011) nmol x L(-1), respectively. Compared with parental cells, the values of resistant fold for KBv200, MCF-7/ADR and HepG2/mdr1 cells to lidamycin were 6.8, 1.6 and 1.3 fold; to adriamycin were 37.2, 181.3 and 8.8 fold; to taxol were 336.8, 49.2 and 40.3 fold, respectively.
CONCLUSIONLidamycin is highly active to multidrug resistant cancer cells. The chemosensitivity of those resistant cancer cells to lidamycin is approximately at the similar level as that of parent cancer cells.
ATP-Binding Cassette, Sub-Family B, Member 1 ; analysis ; genetics ; Aminoglycosides ; pharmacology ; Antibiotics, Antineoplastic ; pharmacology ; Cell Line, Tumor ; Drug Resistance, Multiple ; Drug Resistance, Neoplasm ; Enediynes ; pharmacology ; Genes, MDR ; Humans ; Neoplasms ; drug therapy ; pathology ; Transfection
8.Studies on the pharmacokinetics of lidamycin in mice and dogs using bioassay.
Shu-zhen CHEN ; Zhong-ming TANG ; Yong-su ZHEN
Acta Pharmaceutica Sinica 2004;39(9):700-704
AIMA bioassay method was established for the determination of active concentrations of lidamycin and studied its pharmacokinetics in mice and dogs.
METHODSCytotoxicity of lidamycin in vitro was used to determine drug serum concentrations in vivo.
RESULTSValidity of methodology met the requirements of pharmacokinetic study. The concentration-time profile in mice after iv lidamycin of 100, 50 and 10 microg x kg(-1) was best fitted with 2-compartmental model with T1/2alpha and T1/2beta of 0.77-1.8 min and 5.6-7.2 min, respectively. The AUC were 2851.3, 887.8 and 166.4 microg x min x L(-1), respectively and increased with dose nonlinearly. There were similar trends between AUC and the potency of tumor growth inhibition. After iv lidamycin of 12 microg x kg(-1) in dogs, the concentrations of lidamycin decreased rapidly and the AUC was 16 microg x min x L(-1), which were lower and quicker than those in mice. The levels in serum after second administration at day 15, were lower than those of the first.
CONCLUSIONActive concentrations and pharmacokinetics of lidamycin were obtained by bioassay method successfully. There are species differences and single and multi-dosing differences in the pharmacokinetics of lidamycin.
Aminoglycosides ; blood ; pharmacokinetics ; pharmacology ; Animals ; Antibiotics, Antineoplastic ; blood ; pharmacokinetics ; pharmacology ; Area Under Curve ; Biological Assay ; Dogs ; Enediynes ; Female ; Humans ; Injections, Intravenous ; KB Cells ; metabolism ; Liver Neoplasms ; pathology ; Male ; Mice ; Neoplasm Transplantation ; Sarcoma 180 ; pathology ; Species Specificity
9.Lidamycin inhibits angiogenesis of zebrafish embryo via down-regulation of VEGF.
Li-li DING ; Ming LIU ; Sheng-hua ZHANG ; Xiang-zhong ZHAO ; Ning WU ; Lei CHEN ; Guang-jian WANG ; Xiu-kun LIN
Acta Pharmaceutica Sinica 2010;45(4):456-461
Lidamycin (LDM) is a potent antitumor antibiotic. Previous studies have shown that LDM could inhibit proliferation and migration in endothelial cells. In the present report, the effect of LDM on angiogenesis of zebrafish embryo was studied. The results showed that treatment of zebrafish embryos with LDM resulted in significant inhibition of angiogenesis. Morphological observation, quantitative endogenous alkaline phosphatase (EAP) assay, alkaline phosphatase staining, and transgenic zebrafish assay were performed to evaluate vascular development defects in zebrafish. The results indicated that after the zebrafish embryos were exposed to LDM, angiogenesis defects of zebrafish embryos were observed, including pericardial edema, reduced numbers of circulating red blood cells, suppression of zebrafish vessel growth, and absences of SIV (subintestinal vein). The expression of VEGF was detected by RT-PCR assay, quantitative reverse transcriptase real-time PCR (qRT-PCR) assay and Western blotting analysis. The results revealed that LDM could inhibit the expression of VEGF protein, while the expression of mRNA was not significantly affected. The study suggests that LDM could inhibit the zebrafish embryo angiogenesis by down-regulation ofVEGF expression.
Aminoglycosides
;
pharmacology
;
Animals
;
Animals, Genetically Modified
;
embryology
;
genetics
;
physiology
;
Antibiotics, Antineoplastic
;
pharmacology
;
Down-Regulation
;
Embryo, Nonmammalian
;
drug effects
;
Enediynes
;
pharmacology
;
Neovascularization, Physiologic
;
drug effects
;
genetics
;
RNA, Messenger
;
metabolism
;
Vascular Endothelial Growth Factor A
;
genetics
;
metabolism
;
Zebrafish
;
embryology
;
genetics
;
physiology
10.Binding capability of lidamycin apoprotein to human breast cancer detected by tissue microarrays.
Lin CAI ; Rui-Juan GAO ; Xiao-Zhong GUO ; Yi LI ; Yong-Su ZHEN
Acta Pharmaceutica Sinica 2010;45(5):582-588
This study is to investigate the binding capability of lidamycin apoprotein (LDP), an enediyne-associated apoprotein of the chromoprotein antitumor antibiotic family, to human breast cancer and normal tissues, the correlation of LDP binding capability to human breast cancer tissues and the expression of tumor therapeutic targets such as VEGF and HER2. In this study, the binding capability of LDP to human breast cancer tissues was detected with tissue microarray. The correlation study of LDP binding capability to human breast tumor tissues and relevant therapeutic targets was performed on breast cancer tissue microarrays. Immunocytochemical examination was used to detect the binding capability of LDP to human breast carcinoma MCF-7 cells. As a result, tissue microarray showed that LDP staining of 73.2% (30/41) of breast cancer tissues was positive, whereas that of 48.3% (15/31) of the adjacent normal breast specimens was positive. The difference between the tumor and normal samples was significant (Chi2 = 4.63, P < 0.05). LDP immunoreactivity in breast cancer correlated significantly with the overexpression of VEGF and HER2 (P < 0.001 and < 0.01, r = 0.389 and 0.287, respectively). Determined with confocal immunofluorescent analysis, LDP showed the binding capability to mammary carcinoma MCF-7 cells. It is demonstrated that LDP can bind to human breast cancer tissues and there is significant difference between the breast cancer tissues and the corresponding normal tissues. Notably, the binding reactivity shows positive correlation with the expression of VEGF and HER2 in breast carcinoma tissues. The results imply that LDP may have a potential use as targeting drug carrier in the research and development of new anticancer therapeutics. This study may provide reference for drug combination of LDM and other therapeutic agents.
Aminoglycosides
;
metabolism
;
Antibiotics, Antineoplastic
;
metabolism
;
Apoproteins
;
metabolism
;
Breast Neoplasms
;
metabolism
;
pathology
;
Cell Line, Tumor
;
Enediynes
;
metabolism
;
Female
;
Humans
;
Protein Binding
;
Receptor, ErbB-2
;
metabolism
;
Tissue Array Analysis
;
methods
;
Vascular Endothelial Growth Factor A
;
metabolism